Q3 2022 Results slide image

Q3 2022 Results

Company overview Financial review 2022 priorities Appendix References Vas Narasimhan Chief Executive Officer 27 Investor Relations | Q3 2022 Results NOVARTIS | Reimagining Medicine
View entire presentation